Urothelial cancer stem cells

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 1400-1415

  Dimov, Irena ^a   Visnjic, Milan ^a   Stefanovic, Vladisav ^a  

^a UNIVERSITY OF NI   (Serbia)

Author keywords

Bladder cancer; Cancer stem cell; Therapy; Tumorigenesis; Urothelium

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CD133 ANTIGEN; HERMES ANTIGEN; LAMININ RECEPTOR; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYCOMB GROUP PROTEIN; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; GENE EXPRESSION PROFILING; HUMAN; LUNG CANCER; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; STEM CELL; TARGET CELL DESTRUCTION; URINARY TRACT CANCER; UROTHELIAL CELL CARCINOMA; UROTHELIUM;

CARCINOMA, TRANSITIONAL CELL; CELL DIFFERENTIATION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 77957952256     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.138     Document Type: Review

References (123)

1. Clarke, M.F., Dick, J.E., Dirks, P., Eaves, C.J., Jamieson, C.H.M., Jones, D.L., Visvader, J., Weissman, I.L., and Wahl, G.M. (2006) Cancer stem cells - perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 66, 9339-9344. (Pubitemid 44623625)
2. Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001) Stem cells, cancer and cancer stem cells. Nature 414, 105-111.
3. Beachy, P.A., Karhadkar, S.S., and Berman, D.M. (2004) Tissue repair and stem cell renewal in carcinogenesis. Nature 432, 324-331. (Pubitemid 39551660)
4. Mimeault, M., Hauke, R., Mehta, P.P., and Batra, S.K. (2007) Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J. Cell. Mol. Med. 11, 981-1011. (Pubitemid 350037046)
5. Linheng Li, L. and Neaves, W.B. (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 66, 4553-4557.
6. Li, F., Tiede, B., Massagué, J., and Kang, Y. (2007) Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 17, 3-14. (Pubitemid 46096419)
7. Huntly, B.J.P. and Gilliland, D.G. (2005) Cancer biology: summing up cancer stem cells. Nature 435, 1169-1170. (Pubitemid 40943069)
8. Sánchez-García, I., Vicente-Dueñas, C., and Cobaleda, C. (2007) The theoretical basis of cancer-stem-cell-based therapeutics of cancer: can it be put into practice? Bioassays 29, 1269-1280. (Pubitemid 350221795)
9. Polyak, K. and Weinberg, R.A. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273.
10. Baumann, M., Krause, M., and Hill, R. (2008) Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 8, 545-554. (Pubitemid 351881850)
11. Gedye, C., Davidson, A.-J., Elmes, M.R., Cebon, J., Bolton. D., and Davis, I.D. (2009) Cancer stem cells in urologic cancers. Urol. Oncol. [Epub ahead of print]
12. Chan, K., Espinosa, I., Chao, M., Wong, D., Ailles, L., Diehn, M., Gill, H., Presti, J., Chang, H.Y., van de Rijn, M., Shortliffe, L., and Weissman, I.L. (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. U. S. A. 106, 14016-14021.
13. Lewis, S.A. (2000) Everything you wanted to know about the bladder epitelium, but were afraid to ask. Am. J. Physiol. Renal Physiol. 278, F867-F874. (Pubitemid 30441352)
14. Dyrskjøt, L., Kruhøffer, M., Thykjaer, T., Marcussen, N., Jensen, J.L., Møller, K., Torben, F., and Ørntoft, T.F. (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64, 4040-4048.
15. Brandt, W.D., Matsui, W., Rosenberg, J.E., He, X., Ling, S., Schaeffer, E.M., and Berman, D.M. (2009) Urothelial carcinoma: stem cells on the edge.Cancer Metastasis Rev. 28, 291-304.
16. Lin, Z., Kim, H., Park, H., Kim, Y., Cheon, J., and Kim, I. (2003) The expression of bcl-2 and bcl-6 in normal and malignant transitional epithelium. Urol. Res. 31, 272-275. (Pubitemid 37122172)
17. Vischioni, B., van der Valk, P., Span, S.W., Kruyt, A.E., Rodrigues, J.A., and Giaccone, G. (2005) Expression and localisation of inhibitor of apoptosis proteins in normal human tissues. Hum. Pathol. 37, 78-86.
18. Kurzrock, E.A., Lieu, D.K., de Graffenried, L.A., Chan, C.W., and Isseroff, R.R. (2008) Label-retaining cells of the bladder: candidate urothelial stem cells. Am. J. Physiol. Renal Physiol. 294, F1415-F1421.
19. Pascal, L.E., Deutch, E.W., Campbell, D.S., Korb, M., True, L.D., and Liu, A.Y. (2007) The urologic epithelial stem cell database (UESC) - a web tool for cell type specific gene expression and immunohistochemistry images of prostate and bladder. BMC Urol. 7, 19. (Pubitemid 351207863)
20. Wu, X.-R. (2005) Urothelial tumorigenesis: a tale of different pathways. Nat. Rev. Cancer 5, 713-725.
21. He, X., Marchionni, L., Hansel, D.E., Yu, W., Sood, A., Yang, J., Parmigiani, G., Matsui, W., and Berman, D.M. (2009) Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cell 27, 1487-1495.
22. Hoglund, M. (2007) Bladder cancer, a two phased disease? Semin. Cancer Biol. 17, 225-232.
23. Hartmann, A., Schlake, G., Zaak, D., Hungerhuber, E., Hofstetter, A., Hofstaedter, F., and Knuechel, R. (2002) Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 62, 809-818. (Pubitemid 34126958)
24. Obermann, E.C., Junker, K., Stoehr, R., Dietmaier, W., Zaak, D., Schubert, J., Hofstaedter, F., Knuechel, R., and Hartmann, A. (2003) Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J. Pathol. 199, 50-57.
25. Muto, S., Horie, S., Takahashi, S., Tomita, K., and Kitamura, T. (2000) Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res. 60, 4021-4025.
26. Stoehr, R., Zietz, S., Burger, M., Filbeck, T., Denzinger, S., Ellen, C., Obermann, E.C., Hammerschmied, C., Wieland, W.F., Knuechel, R., and Hartmann, A. (2005) Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur. Urol. 47, 58-63.
27. van der Kwast, T.H. and Bharati, B. (2009) Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling. Curr. Opin. Urol. 19, 516-521.
28. Hoglund, M. (2006) On the origin of syn- and metachronous urothelial carcinomas. Eur. Urol. 51, 1185-1193.
29. Lindgren, D., Gudjonsson, S., Jee, K.J., Liedberg, F., Aits, S., Andersson, A., Chebil, G., Borg, A., Knuutila, S., Fioretos, T., Mansson, W., and Höglund, M. (2008) Recurrent and multiple bladder tumors show conserved expression profiles. BMC Cancer 8, 183.
30. Klonisch, T., Wiechec, E., Hombach-Klonisch, S., Ande, R.S., Wesselborg, S., Schulze-Osthoff. K., and Los, M. (2008) Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med.14, 450-460.
31. Gao, J.X. (2008) Cancer stem cells: the lessons from pre-cancerous stem cells. J. Cell. Mol. Med. 12, 67-96.
32. Thievessen, I., Seifert, H.H., Swiatkowski, S., Florl, A.R., and Schulz, W.A. (2003) E-cadherin involved in inactivation of WNT/β-catenin signalling in urothelial carcinoma and normal urothelial cells. Br. J. Cancer 88, 1932-1938.
33. Reya, T. and Clevers, H. (2005) Wnt signalling in stem cells and cancer. Nature 434, 349-354.
34. Fodde, R. and Brabletz, T. (2007) Wnt/β-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 19, 150-158.
35. Nusse, R. (2008) Wnt signaling and stem cell control. Cell Res. 18, 523-527.
36. Taipale, J. and Beachy, P.A. (2001) The Hedgehog and Wnt signaling pathways in cancer. Nature 411, 349-354.
37. Bui, T.D., O'Brien, T., Crew, J., Cranston, D., and Harris, A.L. (1998) High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer. Br. J. Cancer 77, 319-324.
38. Kastritis, E., Murray, S., Kyriakou, F., Horti, M., Tamvakis, N., Kavantzas, N., Patsouris, E.S., Noni, A., Legaki, S., Dimopoulos, M.A., and Bamias, A. (2009) Somatic mutations of adenomatous polyposis coli gene and nuclear β-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int. J. Cancer 124, 103-108.
39. Stoehr, R., Krieg, R.C., Knuechel, R., Hofstaedter, F., Pilarsky, C., Zaak, D., Schmitt, R., and Hartmann, A. (2002) No evidence for involvement of beta-catenin and APC in urothelial carcinomas. Int. J. Oncol. 20, 905-911.
40. Urakami, S., Shiina, H., Enokida, H., Kawakami, T., Tokizane, T., Ogishima, T., Tanaka, Y., Li, L.-C., Ribeiro-Filho, L.A., Terashima, M., Kikuno, N., Adachi, H., Yoneda, T., Kishi, H., Shigeno, K., Konety, B.R., Igawa, M., and Dahiya, R. (2006) Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin. Cancer Res. 12, 383-391.
41. Karam, J.A., Shariat, S.F., Huang, H.Y., Pong, R.-C., Ashfaq, R., Shapiro, E., Lotan, Y., Sagalowsky, A.I., Wu, X.R., and Hsieh, J.-T. (2007) Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin. Cancer Res. 13, 4400-4406.
42. Urakami, S., Shiina, H., Enokida, H., Kawakami, T., Kawamoto, K., Hirata, H., Tanaka, Y., Kikuno, N., Nakagawa, M, Igawa, M., and Dahiya, R. (2006) Combination analysis of hypermethylated wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin. Cancer Res.12, 2109-2116.
43. Tang, Y., Simoneau, A.R., Liao, W.-X., Yi, G., Hope, C., Liu, F., Li, S., Xie, J., Holcombe, R.F., Jurnak, F.A., Mercola, D., Hoang, B.H., and Zi, X. (2009) WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol. Cancer Ther. 8, 458-468.
44. Saeb-Parsy, K., Veerakumarasivam, A., Wallard, M.J., Thorne, N., Kawano, Y., Murphy, G., Neal, D.E., Mills, I.G., and Kelly, J.D. (2008) MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3. Br. J. Cancer 99, 663-669.
45. Barker, N. and Clevers, H. (2006) Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 5, 997-1014.
46. Stockinger, A., Eger, A., Wolf, J., Beug, H., and Foisner, R. (2001) E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. J. Cell Biol. 154, 1185-1196.
47. Tsukino, H., Kuroda, Y., Nakao, H., Imai, H., Inatomi, H., Kohshi, K., Osada, Y., and Katoh, T. (2003) E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett. 195, 53-58. (Pubitemid 36588978)
48. Nelson, W.J. and Nusse, R. (2004) Convergence of Wnt, beta catenin, and cadherin pathways. Science 303, 1483-1487.
49. Stepan, A., Mǎrgǎritescu, C.L., Simionescu, C., and Ciurea, R. (2009) E-cadherin and p63 immunoexpression in dysplastic lesions and urothelial carcinomas of the bladder. Rom. J. Morphol. Embryol. 50, 461-465.
50. Arance, A., Fabra, A., and Germá, J.R. (2000) Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer. Eur. J. Cancer 36, 357-362.
51. Koga, F., Kawakami, S., Kumagai, J., Takizawa, T., Ando, N., Arai, G., Kageyama, Y., and Kihara, K. (2003) Impaired ΔNp63 expression associates with reduced β-catenin and aggressive phenotypes of urothelial neoplasms Br. J. Cancer 88, 740-747.
52. Langner, C., Ratshek, M., Tsybrovskyy, O., Schips, L., and Zigeuner, R. (2003) P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. J. Histochem. Cytochem. 51, 1097-1099.
53. Di Como, C.J., Urist, M.J., Babayan, I., Drobnjak, M., Hedvat, C.V., Teruya-Feldstein, J., Pohar, K., Hoos, A., and Cordon-Cardo, C. (2002) P63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 8, 494-501.
54. Fukushima, H., Koga, F., Kawakami, S., Fujii, Y., Yoshida, S., Ratovitski, E., Trink, B., and Kihara, K. (2009) Loss of ΔNp63α promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. Cancer Res. 69, 9263-9270.
55. Baumgart, E., Cohen, M.S., Neto, B.S., Micah, A., Jacobs, M.A., Wotkowicz, C., Rieger-Christ, M.K., Biolo, A., Zeheb, R., Loda, M., Libertino, J.A., and Summerhayes, I.C. (2007) Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin. Cancer Res. 13, 1685-1694.
56. Rieger-Christ, K.M., Cain, J.W., Braasch, J.W., Dugan, J.M., Silverman, M.I., Bouyounes, B., Libertino, J.A., and Summerhayes, J.C.(2001) Expression of classic cadherins type I in urothelial neoplastic progression. Hum. Pathol. 32, 18-23.
57. Shimoyama, Y., Hirohashi, S., Hirano, S., Noguchi, M., Shimosato, Y., Takeichi, M., and Abe, O. (1989) Cadherin cell adhesion molecules in human epithelial tissues and carcinomas. Cancer Res. 49, 2128-2133.
58. Takeichi, M. (1991) Cadherin cell adhesion receptors as a morphogenic regulator. Science 251, 1451-1455.
59. Moltzahn, F.R, Volkmen, J.-P., Rottke, D., and Ackermann, R. (2008) Cancer stem cells - lessons from Hercules to fight Hydra. Urol. Oncol. 26, 581-589.
60. Bolós, V., Blanco, M., Medina, V., Aparicio, G., Díaz-Prado, S., and Grande, E. (2009) Notch signalling in cancer stem cells. Clin. Transl. Oncol. 11, 11-19.
61. Miele, L., Golde, T., and Osborne, B. (2006) Notch signaling in cancer. Curr. Mol. Med. 6, 905-918.
62. Watt, F.M., Estrach, S., and Amble, C.A. (2008) Epidermal Notch signalling: differentiation, cancer and adhesion. Curr. Opin. Cell Biol. 20, 171-179.
63. Nicolas, M., Wolfer, A., Raj, K., Kummer, J.A., Mill, P., van Noort, M., Hui, C.C., Clevers, H., Dotto, G.P., and Radtke, F. (2003) Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 33, 416-421.
64. Thélu, J., Rossio, P., and Favier, B. (2002) Notch signalling is linked to epidermal cell differentiation level in basal cell carcinoma, psoriasis and wound healing. BMC Dermatol. 2, 7.
65. Shi, T., Xu, H., Wei, J., Ai, X., Ma, X., Wang, B., Ju, Z., Zhang, G., Wang, C., Wu. Z., and Zhang, X. (2008) Association of low expression of Notch-1 and Jagged-1 in human papillary bladder cancer and shorter survival. J. Urol. 180, 361-366.
66. Daher, A., de Boer, W.I., El-Marjou, A., van der Kwast, T., Abbou, C.C., Thiery, J.P., Radvanyi, F., and Chopin, D.K. (2003) Epidermal growth factor receptor regulates normal urothelial regeneration. Lab. Invest. 83, 1333-1341.
67. Varley, C., Hill, G., Pellegrin, S., Shaw, N.J., Selby, P.J.,Trejdosiewicz, L.K., and Southgate, J. (2005) Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. Exp. Cell Res. 306, 216-229.
68. MacLaine, N.J., Wood, M.D., Holder, J.C., Rees, R.W., and Southgate, J. (2008) Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Mol. Cancer Res. 6, 53-63.
69. Kolev, V., Mandinova, A., Guinea-Viniegra, J., Hu, B., Lefort, K., Lambertini, C., Neel, V., Dummer, R., Wagner, E.F., and Dotto, G.P. (2008) EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat. Cell Biol. 10, 902-911.
70. Thurston, G. and Kitajewski, J. (2008) VEGF and Delta-Notch: interacting signalling pathways in tumor angiogenesis. Br. J. Cancer 99, 1204-1209.
71. Mailhos, C., Modlich, U., Lewis, J., Harris, A., Bicknell, R., and Ish-Horowicz, D. (2001) Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69, 135-144.
72. Patel, N.S., Li, J.L., Generali, D., Poulsom, R., Cranston. D.W., and Harris, A.L. (2005) Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 65, 8690-8697.
73. Li, J.-L., Sainson, R.C.A., Shi, W., Leek, R., Harrington, L.S., Preusser, M., Biswas, S., Turley, H., Heikamp, E., Hainfellner, J.A., and Harris, A.L. (2007) Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 67, 11244-11253.
74. Patel, N.S., Dobbie, M.S., Rochester, M., Steers, G., Poulsom, R., Monnier, K.L., Cranston, D.W., Li, J.-L., and Harris, A.L. (2006) Up-regulation of endothelial Delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin. Cancer Res. 12, 4836-4844.
75. Yan, M. and Plowman, G.D. (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res. 13, 7243-7246.
76. Noguera-Troise, I., Daly, C., Papadopoulos, N.J., Coetzee, S., Boland, P., Gale, N.W., Lin, H.C., Yancopoulos, G.D., and Thurston, G. (2006) Blockade of Dll4 inhibits tumor growth by promoting non-productive angiogenesis. Nature 444, 1032-1037.
77. Thurston, G., Noguera-Troise, I., and Yancopoulos, G.D. (2007) The Delta paradox: DLL4 blockade leads to more tumor vessels but less tumor growth. Nat. Rev. Cancer 7, 327-331.
78. Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.C., Chanthery, Y., Kowalski, J., Watts, R.J., Callahan, C., Kasman, I., Singh, M., Chien, M., Tan, C., Hongo, J.A., de Sauvage, F., Plowman, G., and Yan, M. (2006) Inhibition of Dll4 signalling inhibits tumor growth by deregulating angiogenesis. Nature 444, 1083-1087.
79. Zeng, Q., Li, S., Chepeha, D.B., Giordano, T.J., Li, J., Zhang, H., Polverini, P.J., Nor, J., Kitajewski, J., and Wang, C.Y. (2005) Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8, 13-23.
80. Sainson, R.C.A. and Harris, A.L. (2008) Regulation of angiogenesis by homotypic and heterotypic Notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis 11, 41-51.
81. Di, C.A. and Pandolfi, P.P. (2000) The multiple roles of PTEN in tumor suppression. Cell 100, 387-390.
82. Parsons, R. and Simpson, L. (2003) PTEN and cancer. Methods Mol. Biol. 222, 147-166.
83. Yoo, L.I., Liu, D.W., Vu, S.L., Bronson, R.T., Wu, H., and Yuan, J. (2006) Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner. Cancer Res. 66, 1929-1939.
84. Hill, R. and Wu, H. (2009) PTEN, stem cells, and cancer stem cells. J. Biol. Chem. 284, 11755-11759.
85. Luo, J., Manning, B.D., and Cantley, L.C. (2003) Targeting the PI3KAkt pathway in human cancer: rationale and promise. Cancer Cell 4, 257-262.
86. Puzio-Kuter, A.M., Castillo-Martin, M., Kinkade, C.W., Wang, X., Shen, T.H., Matos, T., Shen, M.M., Cordon-Cardo, C., and Abate-Shen, C. (2009) Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23, 675-680.
87. Tsuruta, H., Kishimoto, H., Sasaki, T., Horie, Y., Natsui, M., Shibata, Y., Hamada, K., Yajima, N., Kawahara, K, Sasaki, M., Tsuchiya, N., Enomoto, K., Mak, T.W., Nakano, T., Habuchi, T., and Suzuki, A. (2006) Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res. 66, 8389-8395.
88. Freeman, D.J., Li, A.G., Wei, G., Li, H.H., Kertesz, N., Lesche, R., Whale, A.D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R.D., Liu, X., and Wu, H. (2003) PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3, 117-130.
89. Shrader, M., Pino, M.S., Lashinger, L., Bar-Eli, M., Adam, L., Dinney, C.P.N., and McConkey, D.J. (2007) Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 67, 1430-1435.
90. Seager, C.M., Puzio-Kuter, A.M., Patel, T., Jain, S., Cordon-Cardo, C., Mc Kiernan, J., and Abate-Shen, C.(2009) Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer . Cancer Prev. Res. 2, 1008-1014.
91. Liu, J., Babaian, D.C., Liebert, M., Steck, P.A., and Kagan, J. (2000) Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. Mol. Carcinog. 29, 143-150.
92. Sansal, I. and Sellers, W.R. (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22, 2954-2963.
93. Wu, X., Obata, T, Khan, Q., Highshaw, R.A., De Vere White, R., and Sweeney, C. (2004) The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int. 93, 143-150.
94. Koksal, I.T., Yasar, D., Dirice, E., Usta, M.F., Karauzum, S., Luleci, G., Baykara, M., and Sanlioglu, S. (2005) Differential PTEN protein expression profiles in superficial versus invasive bladder cancers. Urol. Int. 75, 102-106.
95. Wang, D.S., Rieger-Christ, K., Latini, J.M., Moinzadeh, A., Stoffel, J., Pezza, J.A., Saini, K., Libertino, J.A., and Summerhayes, I.C. (2000) Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int. J. Cancer 88, 620-625.
96. Aveyard, J.S., Skilleter, A., Habuchi, T., and Knowles, M.A. (1999) Somatic mutation of PTEN in bladder carcinoma. Br. J. Cancer 80, 904-908.
97. Platt, F.M., Hurst, C.D., Taylor, C.F., Gregory, W.M., Harnden, P., and Knowles, M.A. (2009) Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin. Cancer Res. 15, 6008-6017.
98. Freeman, D.J., Li, A.G., Wei, G., Li, H.H., Kertesz, N., Lesche, R., Whale, A.D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R.D., Liu, X., and Wu, H. (2003) PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.Cancer Cell 3, 97-99.
99. Li, A.G., Piluso, L.G., Cai, X., Wei, G., Sellers, W.R., and Liu, X. (2006) Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol. Cell 23, 575-587.
100. Blanco-Aparicio, C., Renner, O., Leal, J.F.M., and Carnero, A. (2007) PTEN, more than the AKT pathway. Carcinogenesis 28, 1379-1386.
101. Jacobs, J.J. and van Lohuizen, M. (2002) Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim. Biophys. Acta 1602, 151-161.
102. Sauvageau, M. and Sauvageau, G. (2008) Polycomb group genes: keeping stem cell activity in balance. PLoS Biol. 6, e113.
103. Park, I.K., Morrison, S.J., and Clarke, M.F. (2004) Bmi-1, stem cells, and senescence regulation. J. Clin. Invest. 113, 175-179.
104. Shafaroudi, A.M., Mowla, S.J., Ziaee, S.A.-M., Bahrami, A.-R., Atlasi, Y., and Malakootian, M. (2008) Overexpression of BMI1, a Polycomb group repressor protein, in bladder tumors. Urol. J. 5, 99-105.
105. Qin, Z.-K., Yang, J.-A., Ye, Y.-L., Zhang, X., Xu, L.-H., Zhou, F.-J., Han, H., Liu, Z.-W., Song, L.-B., and Zeng, M.-S. (2009) Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer 9, 61.
106. Hinz, S., Kempkensteffen, C., Christoph, F., Krause, H., Schrader, M., Schostak, M., Miller, K., and Weikert, S. (2008) Expression parameters of the Polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance. Tumor Biol. 29, 323-329.
107. Glinsky, G.V., Berezovska, O., and Glinskii, A.B. (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115, 1503-1521.
108. Weikert, S., Christoph, F., Kollermann, J., Markus, M., Mark, M., Kurt, M., and Hanset, K. (2005) Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. Med. 16, 349-353.
109. Bracken, A.P., Pasini, D., Capra, M., Prosperini, E., Colli, E., and Helin, K. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323-5335.
110. Raman, J.D., Mongan, N.P., Tickoo, S.K., Boorjian, S.A., Scherr, D.S., and Gudas, L.J. (2005) Increased expression of the Polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 11, 8570-8756.
111. Gieni, R.S. and Hendzel, M.J. (2009) Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer. Biochem. Cell Biol. 87, 711-746.
112. Liu, B.B., Qin, L.X., and Liu, Y.K. (2005) Adult stem cells and cancer stem cells: tie or tear apart? J. Cancer Res. Clin. Oncol. 166, 545-555.
113. Atlasi, Y., Mowla, S.J., Ziaee, S.A., and Bahrami, A.R. (2007) OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int. J. Cancer 120, 1598-1602.
114. Chang, C.-C., Shieh, G.-S., Wu, P., Lin, C.-C., Shiau, A.-L., and Wu, C.-L. (2008) Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res. 68, 6281-6291.
115. Naor, D., Nedvetzki, S. , Golan, I., Melnik, L., and Faitelson, Y. (2002) CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 39, 527-579.
116. Hodges, K.B., Lopez-Beltran, A., Davidson, D.D., Montironi, R., and Cheng, L. (2009) Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum. Pathol. 41, 155-162.
117. Mototsugu, M., Hideaki, M., Sadao, K., and Isao, H. (2004) Over expression of CD44V8-10 in human bladder cancer cells decreases their interaction with hyaluronic acid and potentiates their malignant progression. J. Urol. 171, 426-430.
118. Miyake, H., Eto, H., Arakawa, S., Kamidono, S., and Hara, I. (2002) Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J. Urol. 167, 1282-1287.
119. Yang, Y.M. and Chang, J.W. (2008) Bladder cancer initiating cells (BCICs) are among EMA.CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest. 26, 725-733.
120. Liang, F.-X., Bosland, M.C., Huang, H., Romih, R, Baptiste, S., Deng, F.-M., Wu, X.-R., Shapiro, E., and Sun, T.-T. (2005) Cellular basis of urothelial squamous metaplasia: roles of lineage heterogeneity and cell replacement. J. Cell Biol. 171, 835-844.
121. Hartmann, A. (2003) Molecular changes in development and progression of urothelial carcinoma. Verh. Dtsch. Ges. Pathol. 87, 172-184.
122. Chen, L., Shen, R., Ye, Y., Pu, X.-A., Liu, X., Duan, W., Wen, J., Zimmerer, J., Wang, Y., Liu, Y., Lasky, L.C., Hereema, N.A., Perroti, D., Ozato, K., Kuramochi-Miyagawa, S., Nakano, T., Yates, A.J., Carson, W.E., III, Lin, H., Barsky, S.H., and Gao, J.X. (2007) Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS One 2(3), e293
123. Mysorekar, I.U., Mulvey, M.A., Hultgren, S.J., and Gordon, J.I. (2002) Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli. J. Biol. Chem. 227, 7412-7419.